Antimmune B.V.'s Retoleran therapeutic vaccine technology delivers whole protein antigens to down-regulate pro-inflammatory T cells and induce antigen-specific tolerance and treat autoimmune diseases. The company expects that using the entire disease-specific antigen could result in more complete down-regulation of the immune response than tolerizing compounds that only use antigen fragments.

The technology consists of an undisclosed molecule that is combined with an autoimmune disease antigen of the company's choosing.